• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma.卡瑞利珠单抗——靶向一种新型程序性死亡受体1表位治疗肝细胞癌
Ann Transl Med. 2020 Dec;8(23):1614. doi: 10.21037/atm-2020-115.
2
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
3
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.卡瑞利珠单抗治疗既往接受过治疗的晚期肝细胞癌患者的多中心、开放标签、平行分组、随机、Ⅱ期临床试验。
Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26.
4
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.抗 PD-1 单药治疗、单纯化疗及其联合治疗在晚期鼻咽癌中的比较安全性和疗效：来自标志性试验最新进展的研究结果。
J Immunother Cancer. 2019 Jun 25;7(1):159. doi: 10.1186/s40425-019-0636-7.
5
Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.低剂量地西他滨联合抗 PD-1 抗体卡瑞利珠单抗治疗复发/难治性经典型霍奇金淋巴瘤。
J Clin Oncol. 2019 Jun 10;37(17):1479-1489. doi: 10.1200/JCO.18.02151. Epub 2019 Apr 30.
6
A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.肺多形性癌对卡瑞利珠单抗（PD1单克隆抗体）单药治疗的部分缓解：一例报告
Onco Targets Ther. 2020 Dec 3;13:12471-12476. doi: 10.2147/OTT.S279004. eCollection 2020.
7
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.卡瑞利珠单抗对比研究者选择的化疗作为晚期或转移性食管鳞癌（ESCORT）二线治疗：一项多中心、随机、开放标签、III 期研究。
Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13.
8
Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature.抗程序性死亡蛋白1（PD-1）阻断剂诱发的放射性肺炎再发：一例病例报告及文献综述
Front Oncol. 2020 Apr 28;10:561. doi: 10.3389/fonc.2020.00561. eCollection 2020.
9
Camrelizumab: First Global Approval.卡瑞利珠单抗：全球首次获批。
Drugs. 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0.
10
Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation.卡瑞利珠单抗在先前接受过卡瑞利珠单抗和微波消融治疗的非小细胞肺癌患者中的再激发治疗。
J Cancer Res Ther. 2020 Sep;16(5):1191-1195. doi: 10.4103/jcrt.JCRT_798_20.

引用本文的文献

1
Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects.外泌体生物标志物与免疫检查点抑制剂：进展与未来展望
Cancer Cell Int. 2025 Jun 24;25(1):234. doi: 10.1186/s12935-025-03806-x.
2
Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.仑伐替尼联合卡瑞利珠单抗治疗后行转化手术治疗晚期肝细胞癌 1 例报告。
World J Surg Oncol. 2023 Jan 31;21(1):29. doi: 10.1186/s12957-023-02910-4.
3
Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis.卡瑞利珠单抗单药治疗和联合治疗癌症的疗效与安全性：一项系统评价和荟萃分析。
Front Oncol. 2021 Jun 25;11:695512. doi: 10.3389/fonc.2021.695512. eCollection 2021.

本文引用的文献

1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
2
Epidemiology of Hepatocellular Carcinoma.肝细胞癌的流行病学
Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288. Epub 2020 Nov 24.
3
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.卡瑞利珠单抗治疗既往接受过治疗的晚期肝细胞癌患者的多中心、开放标签、平行分组、随机、Ⅱ期临床试验。
Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26.
4
mRECIST for HCC: Performance and novel refinements.肝癌的改良RECIST标准：性能与新改进
J Hepatol. 2020 Feb;72(2):288-306. doi: 10.1016/j.jhep.2019.09.026.
5
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
6
Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.鉴定一种以需要 PD-1 Asn58 糖基化的方式靶向 PD-1 的单克隆抗体。
Commun Biol. 2019 Oct 25;2:392. doi: 10.1038/s42003-019-0642-9. eCollection 2019.
7
Molecular and histological correlations in liver cancer.肝癌的分子和组织学相关性。
J Hepatol. 2019 Sep;71(3):616-630. doi: 10.1016/j.jhep.2019.06.001. Epub 2019 Jun 10.
8
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.纳武利尤单抗治疗晚期肝细胞癌：索拉非尼经治亚洲人群队列分析。
J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7.
9
Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210.反应性毛细血管血管瘤：SHR-1210抗PD-1治疗后的一种新型皮肤毒性。
Cancer Biol Med. 2019 Feb;16(1):173-181. doi: 10.20892/j.issn.2095-3941.2018.0172.
10
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.晚期 HCC 的随机试验和终点：PFS 作为生存替代指标的作用。
J Hepatol. 2019 Jun;70(6):1262-1277. doi: 10.1016/j.jhep.2019.01.028. Epub 2019 Mar 31.

Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma.

作者信息

Rakké Yannick Sebastiaan, Sprengers Dave, Kwekkeboom Jaap, IJzermans Jan Nicolaas Maria

机构信息

Department of Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.

Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.

出版信息

Ann Transl Med. 2020 Dec;8(23):1614. doi: 10.21037/atm-2020-115.

DOI:10.21037/atm-2020-115
PMID:33437813
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7791240/
Abstract
摘要